Sanos A/S

Research site

Denmark Herlev Hovedgade 82, 2730 Herlev, Denmark

9 trials recruiting
Osteoarthritis · Obesity · Arteriosclerosis
Adults and children

About Specializations

Sanos A/S in Herlev, Denmark specialises in clinical trials of conditions such as Osteoarthritis, Obesity, Arteriosclerosis, Overweight, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Herlev Hovedgade 822730 HerlevDenmark

Open in maps ↗

Recruiting now: 9 trials
Conditions studied: 17

More sites in Herlev Denmark

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

40 clinical trials

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational

Denmark

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Osteoarthritis

Recruiting

Efficacy and Safety of LTG-321 Compared with Placebo in Patients with Osteoarthritis of the Knee

Investigational

Efficacy and Safety of LTG-321 Compared with Placebo in Patients with Osteoarthritis of the Knee

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:Latigo Biotherapeutics Inc.

Contact Research Centre

Osteoarthritis

Recruiting

Efficacy of intra‑articular allogeneic peripheral blood mononuclear cells induced to an early apoptotic state versus placebo in adults with primary knee osteoarthritis

Investigational

Efficacy of intra‑articular allogeneic peripheral blood mononuclear cells induced to an early apoptotic state versus placebo in adults with primary knee osteoarthritis

Investigational

Denmark

Participants:18–64 years · 65+ years
Substances:Allogeneic Peripheral Blood Mononuclear Cells Induced To An Early Apoptotic State
Sponsor:Enlivex Therapeutics Ltd.

Contact Research Centre

Obesity+2

Recruiting

A study to evaluate the effects of zenagamtide on weight and pain in patients with overweight or obesity and knee osteoarthritis

Investigational

A study to evaluate the effects of zenagamtide on weight and pain in patients with overweight or obesity and knee osteoarthritis

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Obesity+2

Recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with overweight or obesity and knee osteoarthritis

Investigational

A study to evaluate the efficacy and safety of zenagamtide in people with overweight or obesity and knee osteoarthritis

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Obesity+2

Recruiting

Study of the efficacy and safety of Eloralintide in adults with knee osteoarthritis and overweight or obesity

Investigational

Study of the efficacy and safety of Eloralintide in adults with knee osteoarthritis and overweight or obesity

Investigational

Denmark

Participants:18–64 years · 65+ years
Substances:LY3841136 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Human papilloma virus immunisation

Recruiting

A study on the long-term effectiveness and safety of nine-valent human papillomavirus vaccine in women aged 16 to 26 years for prevention of cervical cancer

Registered drugNo placebo

A study on the long-term effectiveness and safety of nine-valent human papillomavirus vaccine in women aged 16 to 26 years for prevention of cervical cancer

Registered drugNo placebo

Denmark

Participants:18–64 years · Healthy volunteers
Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hypercholesterolaemia

Not yet recruiting

Effect of laroprovstat/rosuvastatin combination versus laroprovstat, rosuvastatin, and placebo on LDL‑C in hypercholesterolemia patients not previously treated with lipid‑lowering therapy

Investigational

Effect of laroprovstat/rosuvastatin combination versus laroprovstat, rosuvastatin, and placebo on LDL‑C in hypercholesterolemia patients not previously treated with lipid‑lowering therapy

Investigational

Denmark

Participants:18–64 years · 65+ years
Substances:Rosuvastatin
Sponsor:AstraZeneca AB

Contact Research Centre

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites